1.47
-0.01 (-0.68%)
| Previous Close | 1.48 |
| Open | 1.48 |
| Volume | 2,627,130 |
| Avg. Volume (3M) | 3,875,596 |
| Market Cap | 989,016,000 |
| Price / Sales | 1.45 |
| Price / Book | 0.710 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -18.80% |
| Operating Margin (TTM) | -61.78% |
| Diluted EPS (TTM) | -0.190 |
| Quarterly Revenue Growth (YOY) | -2.80% |
| Total Debt/Equity (MRQ) | 36.51% |
| Current Ratio (MRQ) | 2.97 |
| Operating Cash Flow (TTM) | -177.37 M |
| Levered Free Cash Flow (TTM) | -110.04 M |
| Return on Assets (TTM) | -8.97% |
| Return on Equity (TTM) | -9.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Opko Health, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.13 |
|
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 54.47% |
| % Held by Institutions | 28.02% |
| 52 Weeks Range | ||
| Median | 2.25 (53.06%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barrington Research | 08 Nov 2024 | 2.25 (53.06%) | Buy | 1.52 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |